our Premium Content: News alerts, weekly reports and conference planners

GENE:

MMP14 (Matrix Metallopeptidase 14)

News alerts, weekly reports and conference planners

Bioinformatic Analysis of Contrasting Expression Patterns and Molecular Interactions of TIMPs in Breast Cancer: Implications for Tumor Progression and Survival. (PubMed, Pathophysiology)

TIMPs display contrasting expression profiles and distinct pathway associations in breast cancer. TIMP1 emerges as the only consistently overexpressed inhibitor, while TIMP4 appears as a promising prognostic marker with unique MMP correlations that may influence tumor behaviors.

3 days ago

Journal

HER-2 (Human epidermal growth factor receptor 2) • MMP2 (Matrix metallopeptidase 2) • TIMP1 (Tissue inhibitor of metalloproteinases 1) • TIMP2 (TIMP Metallopeptidase Inhibitor 2) • MMP9 (Matrix metallopeptidase 9) • MMP1 (Matrix metallopeptidase 1) • ADAM10 (ADAM Metallopeptidase Domain 10) • ADAM12 (ADAM Metallopeptidase Domain 12) • ADAM15 (ADAM Metallopeptidase Domain 15) • MMP14 (Matrix Metallopeptidase 14) • TIMP3 (TIMP Metallopeptidase Inhibitor 3)

20d

Functional diversity of BAI1 (ADGRB1): From angiostasis to synaptic remodeling and disease therapeutics. (PubMed, iScience)

This review systematically integrates current knowledge on BAI1, focusing on its genomic regulatory mechanisms, structural isoform diversity, and multidimensional biological functions. It also underscores the need to explore the translational potential of BAI1 in oncology, neurodegenerative diseases, and immune dysregulation, which is essential for advancing our understanding of this complex receptor and its therapeutic applications.

20 days ago

Review • Journal

CD36 (thrombospondin receptor) • MMP14 (Matrix Metallopeptidase 14)

26d

Deciphering stromal cell interactions in osteosarcoma highlights CDKN2A and MMP14 as novel diagnostic and therapeutic biomarkers. (PubMed, Eur J Med Res)

This study identified CDKN2A and MMP14 as potential OS biomarkers and elucidated their role within the stromal cell network, suggesting resveratrol as a candidate therapeutic molecule targeting MMP14. The present discoveries provided new insights for understanding the progression mechanisms and developing precise diagnosis and treatment strategies for OS.

26 days ago

Journal

CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CD99 (CD99 Molecule) • MMP14 (Matrix Metallopeptidase 14)

26d

FOSL1 Orchestrates Epigenetic Reprogramming of Anaplastic Thyroid Cancer and Suppresses Natural Killer Cell-Mediated Antitumor Immunity. (PubMed, Cancer Res)

Silencing FOSL1, ADAM9, or MMP9 sensitized ATC cells to NK cell-mediated cytotoxicity in vitro and suppressed ATC growth in vivo. Together, these findings highlight the role of FOSL1 in chromatin remodeling of ATC and in dampening cytotoxic functions of NK cells, thereby providing insights into the development of potential cancer therapeutics.

26 days ago

Journal

ADAM9 (ADAM Metallopeptidase Domain 9) • FOSL1 (FOS Like 1) • MMP9 (Matrix metallopeptidase 9) • MMP14 (Matrix Metallopeptidase 14)

Identification of TMEM59L as a potential diagnosis, prognosis and immunotherapy biomarker for colon adenocarcinoma. (PubMed, Sci Rep)

Cellular experiments demonstrated that TMEM59L overexpression enhanced proliferation, migration, invasion, and induced EMT (decreased E-cadherin; increased N-cadherin, VE-cadherin, and MMP14) in HCT116 cells. TMEM59L shows promise as a diagnostic and prognostic biomarker in COAD, with potential roles in modulating the TME, EMT, and immunotherapy response.

1 month ago

Journal • IO biomarker

CDH1 (Cadherin 1) • CDH2 (Cadherin 2) • CDH5 (Cadherin 5) • MMP14 (Matrix Metallopeptidase 14)

Matrix Metalloproteinase Inhibition in Melanoma. (PubMed, Exp Dermatol)

These findings highlight the promising role of MMP inhibitors in melanoma therapy, suggesting a shift towards more targeted and combinatory treatment strategies. This review aims to provide an up-to-date overview of the advancements and therapeutic prospects of both synthetic and natural MMP inhibitors in melanoma treatment.

1 month ago

Review • Journal

MMP2 (Matrix metallopeptidase 2) • MMP9 (Matrix metallopeptidase 9) • MMP14 (Matrix Metallopeptidase 14)

Targeting matrix metalloproteinase-14 disrupts DNA repair and reduces viability in adrenocortical carcinoma. (PubMed, bioRxiv)

Mechanistically, MMP-14 translocates to the nucleus and binds to chromatin following DNA damage induced by ionizing radiation or cisplatin...These findings reveal a novel nuclear function for MMP-14 in DNA repair and identify MMP-14 as a promising therapeutic target in ACC. Targeting MMP-14 may sensitize ACC tumors to DNA-damaging chemotherapy by impairing the repair of therapy-induced lesions.

1 month ago

Journal

CHEK1 (Checkpoint kinase 1) • MMP14 (Matrix Metallopeptidase 14)

cisplatin

Using transcriptomics and molecular docking to uncover the pharmacological targets and its associated biological mechanisms of paeoniflorigenone in treating bladder cancer. (PubMed, Discov Oncol)

It was initially discovered that PAG exerts its therapeutic effects on bladder cancer by targeting multiple pathways and multiple targets. This finding will enhance our comprehension of the potential mechanism by which PAG combats bladder cancer, and it will serve as a theoretical foundation for future research endeavors.

1 month ago

Journal

TOP2A (DNA topoisomerase 2-alpha) • TGFBR2 (Transforming Growth Factor Beta Receptor 2) • IL17A (Interleukin 17A) • MMP9 (Matrix metallopeptidase 9) • MMP1 (Matrix metallopeptidase 1) • PRSS1 (Serine Protease 1) • MMP14 (Matrix Metallopeptidase 14) • MMP7 (Matrix metallopeptidase 7)

Advances in the use of MT1-MMP-targeted nanobodies and peptides for therapeutic delivery in triple-negative breast cancer. (PubMed, Biomed Pharmacother)

The findings indicate that targeting MT1-MMP with synthetic nanobodies and peptides may establish a basis for customized anti-metastatic therapies in TNBC. The ongoing refinement and enhancement of these strategies may improve therapeutic precision and decrease metastatic progression.

1 month ago

Review • Journal

HER-2 (Human epidermal growth factor receptor 2) • MMP14 (Matrix Metallopeptidase 14)

HER-2 expression

2ms

Multimodal biomarker landscape in vestibular schwannoma. (PubMed, Curr Opin Neurol)

This review outlines emerging circulating, tissue-derived and imaging biomarker candidates in VS that may complement MRI and support more precise diagnosis, monitoring, and individualized management.

2 months ago

Review • Journal

TNFRSF8 (TNF Receptor Superfamily Member 8) • TNFA (Tumor Necrosis Factor-Alpha) • IL2RA (Interleukin 2 receptor, alpha) • CD163 (CD163 Molecule) • MIR155 (MicroRNA 155) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • MMP2 (Matrix metallopeptidase 2) • CCL11 (C-C Motif Chemokine Ligand 11) • MIR142 (MicroRNA 142) • MIR7 (MicroRNA 7) • CD80 (CD80 Molecule) • MMP14 (Matrix Metallopeptidase 14) • TGFBR1 (Transforming Growth Factor Beta Receptor 1) • S100B (S100 Calcium Binding Protein B)

2ms

In Vivo Evaluation of a Self-Excitatory Near-Infrared ImmunoSCIFI Probe. (PubMed, Bioconjug Chem)

These preliminary findings establish that antibody-mediated SCIFI can operate in vivo with favorable signal-to-background performance under physiologically relevant photon attenuation. The study therefore provides a methodological foundation for future SCIFI probes, for which rigorous specificity testing and broader biomarker panels will be pursued separately.

2 months ago

Preclinical • Journal

MMP14 (Matrix Metallopeptidase 14)